Immediate Impact
6 hit
Citing Papers
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
2015 Hit
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
2013 Hit
Works of Lucia Malabarba being referenced
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
2004